Roivant Sciences Ltd. (ROIV)
NEUTRALFundamental
34
Price
$36.47
Market Cap
$26.29B
Part 1 · What the company is worth
Overview
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$8M
Trailing 12 months (through 6/30/2026)
Net Income
$-266M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$-759M
Total Equity
$4.53B
Total Liabilities
$416M
Current Ratio
16.72
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$41.82
Current Price
$36.47
Margin of Safety
+12.8%
Fair Value Range
$39.73 - $43.91
Estimation Methods
Valuation Metrics
P/E Ratio
-
ROE
-6.6%
P/B Ratio
6.21
P/FCF
-
Gross Margin
-
ROIC
-9.4%
Profitability Radar
Value Creation (Economic Moat)
ROIC
-9.4%
WACC
10.5%
ROIC − WACC
-19.9 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (7)
- EPS shows upward trend
- Price CAGR 23.63%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 89% Buy
- Share Dilution -22.5%
Failed (11)
- ROIC -9.4%
- P/B Ratio 6.21
- Operating Margin -7914.8%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -6.1%
- Revenue Growth 5Y -19.1%
- Earnings Surprise avg -2.3%
- Net Margin Trend -3535.0% vs -2111.8%
- Piotroski F-Score 1/9
Unavailable (9)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Serious financial concerns
Earnings Quality
Low quality: investigate accounting
Share Dilution
Buying back shares. Shareholder friendly
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Matthew Gline | CEO & Director | 41 |
| Dr. Eric Venker M.D., Pharm.D. | President & CEO of Immunovant | 38 |
| Dr. Mayukh Sukhatme M.D. | President, Chief Investment Officer & Director | 49 |
| Dr. Frank M. Torti M.B.A., M.D. | President & Vant Chair | 46 |
| Mr. Richard Pulik | Chief Financial Officer | 45 |
| Ms. Jennifer Humes | Chief Accounting Officer | 44 |
| Mr. Ian Rosenblum | Chief Information Officer | - |
| Mr. Sam Kaplan | General Counsel | - |
| Ms. Kelly Graff | Head of People | - |
| Mr. Alex Gasner | Executive Vice President of Roivant Health | - |
Audit Risk
5
Board Risk
7
Compensation Risk
10
Shareholder Rights Risk
4
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for ROIV, sourced from Markets Gazette.
- 19d agoPOSITIVERoivant Expects FDA to Approve First Major Drug
Roivant Sciences Ltd. is anticipating FDA approval for its novel drug targeting a severe skin condition, with a market launch projected for September. CEO Matt Gline expressed optimism about the drug's potential. This development represents a significant milestone for Roivant, potentially unlocking a new revenue stream and validating its research and development pipeline. Investors will be closely watching the official FDA decision, as approval could lead to substantial growth and market share gains in the dermatology sector.
via Markets Gazette